Investors
BayTech Venture Capital
BayTech Venture Capital is a leading European Venture Capital firm with the ambition to help the best entrepreneurs build the most successful companies in their fields of expertise. We invest at an early stage in start-up companies in the sectors Technology and Life Sciences in Western Europe, especially in Germany and France. Our contribution to success in the growth phase of these companies is not limited to capital. The money we provide goes along with our experience in company building and the industry expertise of our investment professionals, access to our world-wide network and the respect for the values and the contribution of the entrepreneurs we work with.
www.baytechventurecapital.deCDC Entreprises
CDC Entreprises, a major private equity player in France, acts toward equity financing of fast and growing SMEs. A wholly-owned subsidiary of Caisse des Dépôts – manages private equity funds of funds and co-investment funds with the mission of promoting the French private equity industry, mainly for its own account. It supports venture and growth capital, from seed to late stage financing, on a local and national level, in order to facilitate high-tech, fast-growing or traditional SMEs up to € 15m per company. CDC Entreprises now implements and manages a new investment programme called "France Investissement" (2006-2012), which aims to promote tomorrow’s French champions at an international level. A total of € 2bn have been allocated to be invested by CDC Entreprises in this programme.
Matignon Investissement et Gestion
Matignon Investissement et Gestion is a French independent management company managing assets of € 250 m invested through four specialised venture capital funds in a variety of sectors ranging from early stage start-ups to diversified industrial groups.
ODYSSEE Venture
ODYSSEE Venture, a venture capital management company established in 1999, invests primarily in high technology, high growth companies, usually acting as lead or co-lead investor. ODYSSEE Venture backs its portfolio companies throughout different development stages (seed funding, product and commercial development, international development, build-up…), and has today more than 300 million euros under management, through 13 FCPI (innovation funds) and 3 FIP (regional funds).
Rothschild
The Rothschild Group has been at the centre of the world's financial markets for over 200 years.Its Paris-based Venture Capital team manages funds backed by leading European institutional investors. The team invests in first-class international projects led by exceptional entrepreneurs, in the Telecom, Semiconductor/EDA, Software and MedTech sectors. It invests between $1 million and $10 million to support companies through all phases of their growth. The team provides insights and expertise through its entrepreneurial and operational background and its access to the worldwide Rothschild network.
SEVENTURE
Active partner of companies with high growth potential, SEVENTURE PARTNERS invests since 1997 in the innovative technology businesses. SEVENTURE PARTNERS manages around € 400 million and invests in Life Sciences and Information Technology all over Europe, through 11 FCPI Banque Populaire Innovation and 2 FCPR (e-Fund and Pre-IPO). The SEVENTURE PARTNERS team and its 12 professionnal investors have a proven track record and deep base of knowledge in technology, entrepreneurship, operations, venture capital, and in the needs generated in a company's growth. SEVENTURE PARTNERS is one of the leading venture capital firm in France and a subsidiary of Natexis Private Equity, the asset management company of Natixis-Banque populaire which manages € 3,1 billion in private equity investments. In lifesciences, our 3 favoured sectors are biotech & pharmaceuticals, medical device and chemical/industrial biotech, but we also consider investments in diagnostics, drug delivery systems, environment, bio-energy, skin care, nutraceuticals, wellness and services. In Information Technologies, SEVENTURE PARTNERS invests in companies developing hardware, software products or components and addressing significant market need with a leading-edge technology or a sustainable competitive advantage.
SGAM AI Private Equity
SGAM AI Private Equity is the department of SGAM Alternative Investments dedicated to the equity investments in private companies. With a team of more than 70 specialists and €1.3 bn under management, SGAM AI Private Equity covers the major asset classes from direct investments (venture capital, expansion capital, LBOs) to indirect investments (funds of funds). With €460 M under management, the Venture Capital team is a key investor in information technologies (semiconductors, network and telecoms, Internet and media, software) and biotechnologies (drug discovery, diagnostics, medical devices and clean tech). The team leverages its broad expertise and international network to qualify investment opportunities and bring value to its portfolio companies.